A simple and rapid LC-MS/MS and CE-MS/MS analytical strategy for the determination of therapeutic peptides in modern immunotherapeutics and biopharmaceutics.

Biopharmaceuticals – immunotherapeutics Capillary electrophoresis Non-Enzymatic digestion Peptide conjugates Tandem mass spectrometry Ultra-high-performance liquid chromatography

Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
10 Sep 2020
Historique:
received: 11 05 2020
revised: 19 06 2020
accepted: 23 06 2020
pubmed: 6 7 2020
medline: 22 6 2021
entrez: 5 7 2020
Statut: ppublish

Résumé

Modern therapy of metabolic, neurodegenerative, inflammation, or cancer diseases is recently based on an immunotherapeutic approach. The peptide conjugates represent innovative and effective therapeutics that are better tolerated and are much more specific than small molecule-based medicines. The nature and manufacturing process of these therapeutics make their analysis very challenging. Here, two robust analytical methods based on an on-line combination of ultra-high-performance liquid chromatography with tandem mass spectrometry (UHPLC-MS/MS) and capillary electrophoresis with tandem mass spectrometry (CE-MS/MS) were developed for fast determination of immunogenic synthetic peptide (peptide sequence CADNLHKVVGQST) in a conjugate with bovine serum albumin (BSA) as a carrier protein and is a peptide, conjugate formulated with a vaccine adjuvant - Alhydrogel® 2 %. An effective non-enzymatic release step of the peptide from the final peptide conjugate based on acid hydrolysis with the use of 2% formic acid was successfully tested and implemented. The proposed methods were validated according to the ICH guideline and parameters such as linearity, precision, and accuracy, the limit of detection (LOD) or limit of quantification (LOQ) were assessed. Calibration curves were linear within the range of 1-30 μg.mL

Identifiants

pubmed: 32622303
pii: S0731-7085(20)31335-2
doi: 10.1016/j.jpba.2020.113449
pii:
doi:

Substances chimiques

Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113449

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Juraj Piestansky (J)

Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32 Bratislava, Slovak Republic; Toxicological and Antidoping Center, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, SK-832 32 Bratislava, Slovak Republic. Electronic address: piestansky@fpharm.uniba.sk.

Peter Barath (P)

Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, SK-845 38 Bratislava, Slovak Republic. Electronic address: chempeto@savba.sk.

Petra Majerova (P)

Institute of Neuroimmunology, Slovak Academy of Sciences, Dubravska cesta 9, SK-845 10 Bratislava, Slovak Republic. Electronic address: petra.majerova@savba.sk.

Jaroslav Galba (J)

Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32 Bratislava, Slovak Republic. Electronic address: galba@fpharm.uniba.sk.

Peter Mikus (P)

Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32 Bratislava, Slovak Republic; Toxicological and Antidoping Center, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, SK-832 32 Bratislava, Slovak Republic. Electronic address: mikus@fpharm.uniba.sk.

Branislav Kovacech (B)

Institute of Neuroimmunology, Slovak Academy of Sciences, Dubravska cesta 9, SK-845 10 Bratislava, Slovak Republic. Electronic address: branislav.kovacech@savba.sk.

Andrej Kovac (A)

Institute of Neuroimmunology, Slovak Academy of Sciences, Dubravska cesta 9, SK-845 10 Bratislava, Slovak Republic. Electronic address: andrej.kovac@savba.sk.

Articles similaires

T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans
Humans Middle Aged Female Male Surveys and Questionnaires
Animals Humans Nickel Mice Immunotherapy

Classifications MeSH